Skip to content

Usefulness of Microbiological Tests in Community-Acquired Pneumonia

Prospective Study on Benefits Derived From Microbiological Tests in Community-Acquired Pneumonia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00312741
Enrollment
250
Registered
2006-04-11
Start date
2006-04-30
Completion date
2008-05-31
Last updated
2009-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-Acquired Pneumonia

Keywords

community-acquired pneumonia, microbiological tests, urinary antigen, selection of antibiotic treatment

Brief summary

The hypothesis is that community-acquired pneumonia is usually a monomicrobial infection. Therefore, early detection of the etiology allows to select the most active, narrow-spectrum, and cheap, and less toxic antibiotic agent.

Detailed description

In community-acquired pneumonia, identification of the etiologic agent has theoretically important advantages. For individual patients, it facilitates the administration of a targeted, narrow-spectrum antibiotic therapy that may improve the efficacy of treatment, and reduces risks of antibiotic-related toxicity. For the community, microbiologic results contribute to understanding the local microbial epidemiology of community-acquired pneumonia and the antimicrobial resistance patterns of pathogens, information that is essential in the instauration or modification of empiric treatment regimens. Guidelines recommend that all admitted patients with community-acquired pneumonia should have a collection of two sets of blood cultures, a good quality sputum sample for Gram stain and culture, a sample of pleural fuid if present and, for severe patients, an urine sample for antigen detection. In contrast, several prospective studies (usually without include urinary tests) concluded that these microbiological studies have limited value in the management of patients admitted with community-acquired pneumonia. In addition, microbiological studies could provide erroneous or incomplete information. Thus, investigations has showed false-positive results from pneumococcal antigen detection in urine caused by a frequent persistence of positivity after infection or a nasopharyngeal or bronchial colonization. Other authors suggested that community-acquired pneumonia is a polymicrobial infection; consequently, despite the detection of a true microorganism, treatment needs to be also addressed against other potential pathogenic agents. The purpose of the study is to assess the clinical and the economic derived from the initial microbiological studies, including antigen detection tests in urine for Streptococcus pneumoniae and Legionella pneumophila, in patients with community-acquired pneumonia. The hypothesis is that community-acquired pneumonia is usually a monomicrobial infection. Therefore, early detection of the etiology allows to select the most active, narrow-spectrum, and cheap, and less toxic antibiotic agent.

Interventions

PROCEDUREempirical versus microbiological guided treatment

Sponsors

Hospital Arnau de Vilanova
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age: 18 years and above * Clinical and radiological diagnosis of community-acquired pneumonia * Informed consent of patient * Hospital admission

Exclusion criteria

* Prior hospital admission (less than 15 days) * Alternative diagnosis at the discharge * Immunosuppression (HIV infection, immunosuppressive therapies, neutropenia) * Risk factors for unusual etiologies * Patient is pregnant

Design outcomes

Primary

MeasureTime frame
Clinical and economic consequences obtained with the antibiotic selection in basis to early mcrobiological results

Secondary

MeasureTime frame
Importance of polimicrobial etiology in community-acquired pneumonia
Practice usefulness of urinary antigen detection tests in pneumonia

Countries

Spain

Contacts

Primary ContactMiquel Falguera, M.D.
mfalguera@comll.cat0034-973248100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026